Publication: A Delphi consensus panel about clinical management of early-stage EGFR-mutated non-small cell lung cancer (NSCLC) in Spain: a Delphi consensus panel study.
Loading...
Identifiers
Date
2022-09-27
Authors
Isla, Dolores
Felip, Enriqueta
Garrido, Pilar
Insa, Amelia
Majem, Margarita
Remon, Jordi
Trigo, Jose M
de Castro, Javier
Advisors
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
This Delphi panel study assessed the level of consensus between medical oncologists on the clinical management of patients with early-stage EGFR-mutated non-small cell lung cancer (NSCLC). A modified two-round Delphi approach was used. A scientific committee comprised of medical oncologists developed an online questionnaire. Delphi panel experts rated their level of agreement with each questionnaire statement on a 9-point Likert scale. The questionnaire included 36 statements from 3 domains (clinical management of early-stage NSCLC: 15 statements; role of adjuvant therapy in early-stage NSCLC: 9 statements; and role of adjuvant therapy in early-stage NSCLC with sensitizing EGFR mutation: 12 statements). In round 1, consensus was reached for 24/36 statements (66.7%). Nine statements that did not achieve consensus after the first round were evaluated in round 2, and none of them reached consensus. Overall, 84.4% of the panelists agreed that EGFR mutation testing should be done after surgery. Consensus was not achieved on whether the implementation of EGFR mutation testing in resected early-stage NSCLC could limit the use of adjuvant osimertinib. The panelists recognized the rationale for the use of osimertinib in the adjuvant scenario (88%) and 72% agreed that it may change the treatment paradigm in stage IB-IIIA EGFR-mutated NSCLC. Consensus was not reached on the inconvenience of prolonged duration of osimertinib. This Delphi study provides valuable insights into relevant questions in the management of early-stage EGFR-mutated NSCLC. However, specific issues remain unresolved. The expert consensus emphasizes the role of adjuvant treatment with osimertinib in this scenario.
Description
MeSH Terms
Humans
Carcinoma, Non-Small-Cell Lung
Spain
Lung Neoplasms
Delphi Technique
Small Cell Lung Carcinoma
ErbB Receptors
Carcinoma, Non-Small-Cell Lung
Spain
Lung Neoplasms
Delphi Technique
Small Cell Lung Carcinoma
ErbB Receptors
DeCS Terms
CIE Terms
Keywords
Adjuvant, Consensus, Delphi method, EGFR-mutated, Non-small cell lung cancer (NSCLC), osimertinib